Outcome of recurrent and persistent disease of malignant ovarian germ cell tumor: A retrospective analysis at King Chulalongkorn Memorial Hospital

Journal of the Medical Association of Thailand

Volumn 89, Issue 2, 2006, Pages 138-144

  Lertkhachonsuk, Ruangsak ^a   Manchana, Tarinee ^a   Termrungruanglert, Wichai ^a   Vasuratna, Apichai ^a   Sittisomwong, Tul ^a   Worasethsin, Pongkasem ^a   Sirisabya, Nakarin ^a   Khemapech, Nipon ^a   Tresukosol, Damrong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Malignant ovarian germ cell tumor; Persistent disease; Recurrent disease

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; GERM CELL TUMOR; HOSPITAL; HUMAN; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; OVARY TUMOR; REVIEW; SALVAGE THERAPY; THAILAND; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGE; ARTICLE; CANCER STAGING; CHILD; FEMALE; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; NEOPLASM; OVARIECTOMY; PATHOLOGY; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGE FACTORS; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; CHILD; COMBINED MODALITY THERAPY; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; OVARIECTOMY; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; THAILAND;

EID: 33645998434     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994; 55(3 Pt 2): S62-72.
2. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990; 8: 715-20.
3. Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12: 701-6.
4. Curtin JP, Morrow CP, D'Ablaing G, Schlaerth JB. Malignant germ cell tumors of the ovary: 20-year report of LAC-USC Women's Hospital. Int J Gynecol Cancer 1994; 4: 29-35.
5. Linasmita V, Srisupundit S, Wilailak S, Tangtrakul S, Israngura N, Bullangpoti S. Recent management of malignant ovarian germ cell tumors: a study of 34 cases. J Obstet Gynaecol Res 1999; 25: 315-20.
6. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993; 71(4 Suppl): 1581-90.
7. Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 1976; 37: 2359-72.
8. Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol 1981; 58: 497-504.
9. Asadourian LA, Taylor HB. Dysgerminoma. An analysis of 105 cases. Obstet Gynecol 1969; 33: 370-9.
10. Gershenson DM, Del Junco G, Copeland LJ, Rutledge FN. Mixed germ cell tumors of the ovary. Obstet Gynecol 1984; 64: 200-6.
11. Schwartz PE. Combination chemotherapy in the management of ovarian germ cell malignancies. Obstet Gynecol 1984; 64: 564-72.
12. Gershenson DM, Kavanagh JJ, Copeland LJ, Del Junco G, Cangir A, Saul PB, et al. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin. Cancer 1986; 57: 1731-7.
13. Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995; 13: 470-6.
14. de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15: 1837-43.
15. Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol 1998; 25: 235-42.
16. Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-35.
17. Williams SD BJ, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrence ovarian germ-cell tumors. Ann Intern Med 1989; 111: 22-7.
18. Lotz JP, Izrael V. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 1995; 16: 858-9.
19. Margolin BK, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996; 14: 2631-7.
20. Chou HH, Lai CH, Wang PN, Tsai KT, Liu HP, Hsueh S. Combination of high-dose chemotherapy, autologous bone marrow/peripheral blood stem cell transplantation, and thoracoscopic surgery in refractory nongestational choriocarcinoma of a 45XO/46XY female: a case report. Gynecol Oncol 1997; 64: 521-5.